Table 2 Demographic data, patient clinical characteristics, site of infection and microorganisms identified

N. of patients

210

138

Gender male. n. (%)

153 (73)

95 (69)

Age (year)

63.0 ± 11.2

70.6 ± 9.9*

BMI (Kg/m²)

27.2 ± 6.3

26.0 ± 5.6

Basal Serum creatinine (mg/L)

1.0 ± 0.4

2.3 ± 1.4*

Basal Creatinine Clearance (ml/min/1.73 m²)

106.4 ± 40.7

37 ± 16.2*

Loading dose (mg/kg)

16.7 ± 4.8

18 ± 2

Mean time to first VSC (hours)

40 ± 3

41 ± 2

Total continuous infusion dose^a (g)

5.4 ± 0.3

3.6 ± 0.8*

Duration of vancomycin therapy (days)

9.0 ± 1.1

9.1 ± 1.6

Nephrotoxicity n. (%)

5 (2.4)

13 (9.4)

Concomitant use of nephrotoxic agents:

Vasopressor n. (%)

32 (15.2)

25 (18.1)

Aminoglycoside. n. (%)

12 (5.7)

9 (6.5)

Ace inhibitor n. (%)

41 (19.5)

21 (15.2)

Type of patient at ICU admission:

Medical n. (%)

119 (56.7)

69 (50.0)

Urgent surgery n. ( %)

7 (3.3)

23 (16.6)^*

Scheduled surgery n.(%)

84 (40.0)

46 (33.4)

Admission diagnosis. n. (%)

Sepsis

63 (30 %)

36 (26)

Respiratory failure without sepsis

43 (20.4)

26 (18.8)

Post surgery

80 (38)

66 (47.8)

Other

24 (11.4)

10 (7.2)

SAPS II (first 24 h)

40.3 ± 8.0

46.2 ± 7.7*

ICU deaths. n. (%)

45 (21.4)

33 (23.9)

Site of infection. n.( %)

Low Respiratory Tract

102 (48.6)

50 (36.2)*

Intra-abdominal

43 (20.5)

44 (31.8)*

Bloodstream

30 (14.3)

6 (4.3)*

Skin and soft tissue

23 (10.9)

38 (27.5)*

Other

12 (5.7)

0*

Microorganisms identified. n. (%)

Staphylococci spp

133 (63.3)

86 (62.3)

Enterococci spp

74 (35.2)

52 (37.7)

Streptococci spp

3 ( 1.4)

0

Vancomycin AUC/ MIC at first determination

468 ± 79

490 ± 84